Probucol in albuminuric type 2 diabetes mellitus patients on renin-angiotensin system blockade

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 36, Issue 10, 2016, Pages 2108-2114

  Jin, Sang Man ^a   Han, Kyung Ah ^b   Yu, Jae Myung ^c   Sohn, Tae Seo ^d   Choi, Sung Hee ^e   Chung, Choon Hee ^f   Park, Ie Byung ^g   Rhee, Eun Jung ^h   Baik, Sei Hyun ⁱ   Park, Tae Sun ^j   Lee, In Kyu ^k   Ko, Seung Hyun ^l   Hwang, You Cheol ^m   Cha, Bong Soo ⁿ   Lee, Hyoung Woo ^o   Nam, Moon Suk ^p   Lee, Moon Kyu ^a  

^a Sungkyunkwan University   (South Korea)

^b Eulji General Hospital   (South Korea)

^c Hallym Medical School   (South Korea)

^d Uijeongbu St Mary's Hospital   (South Korea)

^e Seoul National University Bundang Hospital   (South Korea)

^f Yonsei University Wonju   (South Korea)

^g Gachon University   (South Korea)

^h School of Medicine   (South Korea)

ⁱ Korea University   (South Korea)

^j Chonbuk National University Medical School   (South Korea)

^k Kyungpook National University Hospital   (South Korea)

^l The Catholic University of Korea   (South Korea)

^m Kyung Hee University College of Medicine   (South Korea)

ⁿ Yonsei University College of Medicine   (South Korea)

^o Yeungnam University College of Medicine   (South Korea)

^p Inha University School of Medicine   (South Korea)

more..

Author keywords

albuminuria; antioxidants; diabetic nephropathies; probucol; type 2 diabetes mellitus

Indexed keywords

ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; CREATININE; CYSTATIN C; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OXIDIZED LOW DENSITY LIPOPROTEIN; PROBUCOL; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BIOLOGICAL MARKER; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ALBUMINURIA; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; DEATH; DIABETIC NEPHROPATHY; DIABETIC PATIENT; DIARRHEA; DISEASE DURATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; ENTERITIS; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; RASH; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TOBACCO USE; URINARY EXCRETION; BLOOD; CLINICAL TRIAL; COMPLICATION; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DRUG EFFECTS; DYSLIPIDEMIAS; KIDNEY; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; SOUTH KOREA; TERTIARY CARE CENTER; TIME FACTOR; TREATMENT OUTCOME;

ADULT; AGED; ALBUMINURIA; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTICHOLESTEREMIC AGENTS; BIOMARKERS; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DOUBLE-BLIND METHOD; DYSLIPIDEMIAS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; PROBUCOL; RENIN-ANGIOTENSIN SYSTEM; REPUBLIC OF KOREA; TERTIARY CARE CENTERS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84982813090     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.116.308034     Document Type: Article

References (23)

1. Park CW. Diabetic kidney disease: from epidemiology to clinical perspectives. Diabetes Metab J. 2014;38:252-260. doi: 10.4093/dmj.2014.38.4.252.
2. Diabetic kidney disease: what does the next era hold?. Lancet Diabetes Endocrinol. 2015;3:665.
3. Ha H, Kim KH. Pathogenesis of diabetic nephropathy: the role of oxidative stress and protein kinase C. Diabetes Res Clin Pract. 1999;45:147-151.
4. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414:813-820. doi: 10.1038/414813a.
5. Ha H, Kim C, Son Y, Chung MH, Kim KH. DNA damage in the kidneys of diabetic rats exhibiting microalbuminuria. Free Radic Biol Med. 1994;16:271-274.
6. Horie K, Miyata T, Maeda K, Miyata S, Sugiyama S, Sakai H, van Ypersole de Strihou C, Monnier VM, Witztum JL, Kurokawa K. Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions. Implication for glycoxidative stress in the pathogenesis of diabetic nephropathy. J Clin Invest. 1997;100:2995-3004. doi: 10.1172/JCI119853.
7. Sechi LA, Ceriello A, Griffin CA, Catena C, Amstad P, Schambelan M, Bartoli E. Renal antioxidant enzyme mRNA levels are increased in rats with experimental diabetes mellitus. Diabetologia. 1997;40:23-29. doi: 10.1007/s001250050638.
8. Koya D, Hayashi K, Kitada M, Kashiwagi A, Kikkawa R, Haneda M. Effects of antioxidants in diabetes-induced oxidative stress in the glomeruli of diabetic rats. J Am Soc Nephrol. 2003;14(8 suppl 3):S250-S253.
9. Nishimura M, Sasaki T, Ohishi A, Oishi M, Kono S, Totani Y, Kato Y, Noto Y, Misaki S, Higashi K, Shimada F, Wakasugi H, Inoue K, Hoshiyama Y, Yamada K. Angiotensin-converting enzyme inhibitors and probucol suppress the time-dependent increase in urinary Type IV collagen excretion of Type II diabetes mellitus patients with early diabetic nephropathy. Clin Nephrol. 2001;56:96-103.
10. Endo K, Miyashita Y, Sasaki H, Ohira M, Saiki A, Koide N, Otsuka M, Oyama T, Takeyoshi M, Ito Y, Shirai K. Probucol delays progression of diabetic nephropathy. Diabetes Res Clin Pract. 2006;71:156-163. doi: 10.1016/j.diabres.2005.05.012.
11. Endo K, Saiki A, Yamaguchi T, et al. Probucol suppresses initiation of chronic hemodialysis therapy and renal dysfunction-related death in diabetic nephropathy patients: Sakura study. J Atheroscler Thromb. 2013;20:494-502.
12. Zhu H, Chen X, Cai G, et al. Telmisartan combined with probucol effectively reduces urinary protein in patients with Type 2 diabetes: a randomized, double-blind, placebo-controlled, multi-center clinical study [published online ahead of print October 12, 2015]. J Diabetes. doi: 10.1111/1753-0407.12347. http://onlinelibrary.wiley.com/doi/10.1111/1753-0407.12347/abstract.jsessionid=8D77C102D0AF40F5892943620B8312EF.f02t03.
13. Heinecke JW. Lipoprotein oxidation in cardiovascular disease: chief culprit or innocent bystander?. J Exp Med. 2006;203:813-816. doi: 10.1084/jem.20060218.
14. Wu BJ, Kathir K, Witting PK, Beck K, Choy K, Li C, Croft KD, Mori TA, Tanous D, Adams MR, Lau AK, Stocker R. Antioxidants protect from atherosclerosis by a heme oxygenase-1 pathway that is independent of free radical scavenging. J Exp Med. 2006;203:1117-1127. doi: 10.1084/jem.20052321.
15. Endo K, Miyashita Y, Sasaki H, Ebisuno M, Ohira M, Saiki A, Koide N, Oyama T, Takeyoshi M, Shirai K. Probucol and atorvastatin decrease urinary 8-hydroxy-2'-deoxyguanosine in patients with diabetes and hypercholesterolemia. J Atheroscler Thromb. 2006;13:68-75.
16. Li G, Yin L, Liu T, Zheng X, Xu G, Xu Y, Yuan R, Che J, Liu H, Zhou L, Chen X, He M, Li Y, Wu L, Liu E. Role of probucol in preventing contrastinduced acute kidney injury after coronary interventional procedure. Am J Cardiol. 2009;103:512-514. doi: 10.1016/j.amjcard.2008.10.009.
17. Yin L, Li G, Liu T, et al. Probucol for the prevention of cystatin C-based contrast-induced acute kidney injury following primary or urgent angioplasty: a randomized, controlled trial. Int J Cardiol. 2013;167:426-429. doi: 10.1016/j.ijcard.2012.01.017.
18. Steinberg D. Studies on the mechanism of action of probucol. Am J Cardiol. 1986;57:16H-21H.
19. Tawara K, Tomikawa M, Abiko Y. Mode of action of probucol in reducing serum cholesterol in mice. Jpn J Pharmacol. 1986;40:123-133.
20. Keyamura Y, Nagano C, Kohashi M, Niimi M, Nozako M, Koyama T, Yasufuku R, Imaizumi A, Itabe H, Yoshikawa T. Add-on effect of probucol in atherosclerotic, cholesterol-fed rabbits treated with atorvastatin. PLoS One. 2014;9:e96929. doi: 10.1371/journal.pone.0096929.
21. Witztum JL, Simmons D, Steinberg D, Beltz WF, Weinreb R, Young SG, Lester P, Kelly N, Juliano J. Intensive combination drug therapy of familial hypercholesterolemia with lovastatin, probucol, and colestipol hydrochloride. Circulation. 1989;79:16-28.
22. Tonolo G, Ciccarese M, Brizzi P, Puddu L, Secchi G, Calvia P, Atzeni MM, Melis MG, Maioli M. Reduction of albumin excretion rate in normotensive microalbuminuric type 2 diabetic patients during long-Term simvastatin treatment. Diabetes Care. 1997;20:1891-1895.
23. Usui H, Shikata K, Matsuda M, Okada S, Ogawa D, Yamashita T, Hida K, Satoh M, Wada J, Makino H. HMG-CoA reductase inhibitor ameliorates diabetic nephropathy by its pleiotropic effects in rats. Nephrol Dial Transplant. 2003;18:265-272.